|
|
 |
Go back to referring page | |
Main Page |
FUNDAMENTAL REVIEW OF THE
GENERIC DRUGS MARKET
A Report Prepared by OXERA
on behalf of the Department of Health
JULY 2001
Contents
1.
Introduction
PHASE I
2.
Key Findings of the Industry Analysis
3.
Performance of the Current System
4.
Reforms to Pharmacy Reimbursement
5.
Improving Information Flows
6.
Lowering Entry Barriers into Manufacturing
7.
Options for Changing Retail Industry Structure
8.
Centralised Purchasing
9.
Conclusions from Phase I
PHASE II
10.
Enhancing Competition in Generic Manufacturing
11.
The Case for Centralised Purchasing through Tendering
12.
Tendering Options 1 and 2: Full and Partial Tendering of Generic Drugs
13.
Tendering Option 3: Tendering for Buffer Stocks
14.
Tendering Option 4: Tendering for Framework Agreements
15.
Setting Up a Pilot for Tendering Option 2
16.
Impact Analysis
17.
Conclusions and Recommendations
Appendices
A1.
Manufacturing
A2.
Wholesaling
A3. Pharmacy
A4. Licence Alteration
Data
A5. Profitability
Analysis
A6. The UK Hospital
Framework
A7. The US Drugs
System
A8. The Drugs System
in the Netherlands
A9. Tendering for
Medicines in New Zealand
A10. List of
Interviewees and Information Sources
Abbreviations
OXERA Consulting Ltd is registered in England, no. 2589629. Registered office: Blue Boar Court, Alfred Street, Oxford OX1 4EH, UK. Although every effort has been made to ensure the accuracy of the material and the integrity of the analysis presented herein, OXERA Consulting Ltd accepts no liability for any actions taken on the basis of its contents.
OXERA Consulting Ltd is not licensed in the conduct of investment business as
defined in the Financial Services Act 1986. Anyone considering a specific
investment should consult their own broker or other investment adviser. OXERA
Consulting Ltd accepts no liability for any specific investment decision which
must be at the investor’s own risk.
OXERA
Blue Boar Court
Alfred Street
Oxford OX1 4EH
Tel: 01865 253000
Fax: 01865 251172
Email: enquiries@oxera.co.uk
Published by the Department of Health
|
|||||